Portfolio Holdings Detail for ISIN IE00BYXG2H39
| Stock Name / Fund | iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares IV Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300ZP07LMR36K1T02 |
| ETF Ticker | BTEC(USD) LSE |
| ETF Ticker | BTEK(GBP) LSE |
| ETF Ticker | 2B70(EUR) F |
| ETF Ticker | 2B70.DE(EUR) CXE |
| ETF Ticker | BTEC.LS(USD) CXE |
| ETF Ticker | BTEK.LS(GBP) CXE |
| ETF Ticker | BTEC.L(GBP) LSE |
| ETF Ticker | BTEK.L(GBP) LSE |
Holdings detail for CNTA
| Stock Name | Centessa Pharmaceuticals PLC ADR |
| Ticker | CNTA(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US1523091007 |
| LEI | 213800GIDAARDSKOI827 |
Show aggregate CNTA holdings
News associated with CNTA
- Centessa Pharmaceuticals (NASDAQ:CNTA) Coverage Initiated at Oppenheimer
- Oppenheimer began coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA – Free Report) in a research report sent to investors on Friday morning. The firm issued an outperform rating and a $40.00 target price on the stock. CNTA has been the topic of several other research reports. Chardan Capital reaffirmed a “buy” rating and set a […] - 2025-09-01 03:02:48
- Centessa Pharmaceuticals (NASDAQ:CNTA) Earns “Buy” Rating from Chardan Capital
- Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at Chardan Capital in a report issued on Tuesday,Benzinga reports. They currently have a $30.00 price target on the stock. Chardan Capital’s price objective would suggest a potential upside of 75.03% from the stock’s current price. A number of […] - 2025-08-14 03:14:57
- Analysts Set Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Price Target at $28.10
- Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Get Free Report) have earned an average rating of “Buy” from the eleven analysts that are covering the company, Marketbeat.com reports. Eleven equities research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have issued a report on […] - 2025-08-13 03:04:43
- XTX Topco Ltd Increases Position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA)
- XTX Topco Ltd raised its holdings in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Free Report) by 81.0% in the first quarter, Holdings Channel.com reports. The firm owned 41,057 shares of the company’s stock after purchasing an additional 18,377 shares during the period. XTX Topco Ltd’s holdings in Centessa Pharmaceuticals were worth $590,000 […] - 2025-08-06 05:20:57
- Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) CEO Sells $875,600.00 in Stock
- Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Get Free Report) CEO Saurabh Saha sold 55,000 shares of the stock in a transaction on Monday, July 21st. The shares were sold at an average price of $15.92, for a total value of $875,600.00. Following the completion of the sale, the chief executive officer owned 221,017 shares […] - 2025-07-23 05:50:50
- Centessa Pharmaceuticals (NASDAQ:CNTA) Coverage Initiated at Truist Financial
- Investment analysts at Truist Financial initiated coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) in a research report issued to clients and investors on Monday, Marketbeat.com reports. The brokerage set a “buy” rating and a $30.00 price target on the stock. Truist Financial’s target price indicates a potential upside of 85.53% from […] - 2025-07-23 05:10:48
- Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Average Rating of “Buy” from Brokerages
- Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Get Free Report) have received an average recommendation of “Buy” from the ten ratings firms that are covering the company, Marketbeat Ratings reports. Ten equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have updated […] - 2025-07-16 02:49:05
- Nxera Pharma To Receive $4.8 Mln Milestone As Centessa Advances ORX142 To Phase 1 Study
- (RTTNews) - Nxera Pharma Co., Ltd. announced it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals under their research collaboration. The payments follow Centessa's initiation of clinical development for ORX142, its second novel orexin receptor 2 (OX - 2025-07-04 04:13:48
- Centessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 3.8% Following Insider Selling
- Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Get Free Report) shares fell 3.8% during trading on Thursday following insider selling activity. The stock traded as low as $12.95 and last traded at $12.93. 65,287 shares were traded during mid-day trading, a decline of 91% from the average session volume of 726,424 shares. The stock had […] - 2025-06-27 02:17:08
- Saurabh Saha Sells 55,000 Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Stock
- Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Get Free Report) CEO Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $12.63, for a total value of $694,650.00. Following the completion of the transaction, the chief executive officer now owns […] - 2025-06-23 05:25:00
- We Did The Math TMSL Can Go To $38
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-10 08:53:34
- Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stake Lowered by Two Sigma Investments LP
- Two Sigma Investments LP reduced its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA – Free Report) by 63.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 37,900 shares of the company’s stock after selling 66,008 shares during the period. […] - 2025-06-09 04:56:44
- Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $27.00 Average PT from Brokerages
- Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) has been given a consensus rating of “Buy” by the ten research firms that are currently covering the stock, Marketbeat reports. Ten research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have updated their coverage on the stock […] - 2025-05-30 03:06:54
- Centessa Pharmaceuticals (NASDAQ:CNTA) Coverage Initiated at Needham & Company LLC
- Stock analysts at Needham & Company LLC assumed coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) in a note issued to investors on Wednesday, MarketBeat reports. The brokerage set a “buy” rating and a $35.00 price target on the stock. Needham & Company LLC’s price objective indicates a potential upside of 167.79% […] - 2025-05-30 02:21:02
- Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Up After Insider Buying Activity
- Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) gapped up before the market opened on Tuesday following insider buying activity. The stock had previously closed at $12.26, but opened at $12.74. Centessa Pharmaceuticals shares last traded at $12.97, with a volume of 107,299 shares trading hands. Specifically, Director Arjun Goyal acquired 417,646 shares of the […] - 2025-05-22 02:32:56
- Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock Holdings Increased by Barclays PLC
- Barclays PLC grew its position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA – Free Report) by 1,414.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,302 shares of the company’s stock after buying an additional 4,952 shares during the period. […] - 2025-05-15 04:31:09
- Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $27.71 Consensus PT from Analysts
- Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) have received a consensus rating of “Buy” from the eight analysts that are currently covering the stock, MarketBeat reports. Eight analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have issued a report on the stock in […] - 2025-05-05 02:34:53
- Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $27.71 Average Price Target from Brokerages
- Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) have been given a consensus rating of “Buy” by the eight brokerages that are currently covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued a report on […] - 2025-04-10 03:07:13
- Centessa Pharmaceuticals (NASDAQ:CNTA) Now Covered by Analysts at Piper Sandler
- Stock analysts at Piper Sandler initiated coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. The brokerage set an “overweight” rating and a $38.00 price target on the stock. Piper Sandler’s target price indicates a potential upside of 187.23% […] - 2025-04-02 03:12:49
- Guggenheim Reaffirms Buy Rating for Centessa Pharmaceuticals (NASDAQ:CNTA)
- Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Guggenheim in a research report issued on Wednesday,Benzinga reports. They presently have a $28.00 price target on the stock. Guggenheim’s target price suggests a potential upside of 92.97% from the stock’s previous close. Several other brokerages have […] - 2025-03-28 05:02:42
- Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells $917,950.00 in Stock
- Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) CEO Saurabh Saha sold 55,000 shares of the business’s stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $16.69, for a total transaction of $917,950.00. Following the transaction, the chief executive officer now owns 276,017 shares of the company’s […] - 2025-03-24 06:04:57
- Analysts Set Centessa Pharmaceuticals plc (NASDAQ:CNTA) Target Price at $25.83
- Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) has earned an average recommendation of “Buy” from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued a report on the stock […] - 2025-02-19 04:12:50
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) CNTA holdings
| Date | Number of CNTA Shares Held | Base Market Value of CNTA Shares | Local Market Value of CNTA Shares | Change in CNTA Shares Held | Change in CNTA Base Value | Current Price per CNTA Share Held | Previous Price per CNTA Share Held |
|---|
| 2026-02-09 (Monday) | 70,463 | USD 1,657,994 | USD 1,657,994 | | | | |
| 2026-02-06 (Friday) | 70,306 | USD 1,651,488 | USD 1,651,488 | 157 | USD -115,565 | USD 23.49 | USD 25.19 |
| 2026-02-02 (Monday) | 70,149 | USD 1,767,053 | USD 1,767,053 | 0 | USD 43,492 | USD 25.19 | USD 24.57 |
| 2026-01-30 (Friday) | 70,149 | USD 1,723,561 | USD 1,723,561 | 314 | USD -14,632 | USD 24.57 | USD 24.89 |
| 2026-01-29 (Thursday) | 69,835 | USD 1,738,193 | USD 1,738,193 | 157 | USD -72,738 | USD 24.89 | USD 25.99 |
| 2026-01-27 (Tuesday) | 69,678 | USD 1,810,931 | USD 1,810,931 | 157 | USD 22,156 | USD 25.99 | USD 25.73 |
| 2026-01-26 (Monday) | 69,521 | USD 1,788,775 | USD 1,788,775 | 0 | USD 31,979 | USD 25.73 | USD 25.27 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of CNTA by Blackrock for IE00BYXG2H39
Show aggregate share trades of CNTA| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2026-02-06 | BUY | 157 | | | 23.490* | | - |
| 2026-01-30 | BUY | 314 | 25.150 | 23.820 | 23.953 | USD 7,521 | - |
| 2026-01-29 | BUY | 157 | 25.515 | 24.130 | 24.268 | USD 3,810 | - |
| 2026-01-27 | BUY | 157 | 26.490 | 25.470 | 25.572 | USD 4,015 | - |
| 2026-01-23 | BUY | 314 | 26.000 | 24.110 | 24.299 | USD 7,630 | - |
| 2026-01-22 | BUY | 157 | 24.950 | 23.020 | 23.213 | USD 3,644 | - |
| 2026-01-16 | BUY | 2,900 | 22.850 | 22.070 | 22.148 | USD 64,229 | - |
| 2026-01-15 | BUY | 300 | 22.820 | 21.940 | 22.028 | USD 6,608 | - |
| 2026-01-14 | BUY | 300 | 22.285 | 21.810 | 21.857 | USD 6,557 | - |
| 2026-01-12 | BUY | 300 | 22.430 | 21.549 | 21.637 | USD 6,491 | - |
| 2026-01-09 | BUY | 450 | 23.000 | 22.210 | 22.289 | USD 10,030 | - |
| 2026-01-07 | BUY | 300 | 23.690 | 22.450 | 22.574 | USD 6,772 | - |
| 2026-01-02 | BUY | 150 | 25.065 | 23.490 | 23.647 | USD 3,547 | - |
| 2025-12-30 | BUY | 150 | 25.580 | 24.586 | 24.685 | USD 3,703 | - |
| 2025-12-23 | SELL | -1,800 | 25.580 | 25.030 | 25.085 | USD -45,153 | - |
| 2025-12-19 | SELL | -5,306 | 25.280 | 24.170 | 24.281 | USD -128,835 | - |
| 2025-12-17 | SELL | -815 | 25.970 | 24.810 | 24.926 | USD -20,315 | - |
| 2025-12-16 | SELL | -163 | 26.695 | 25.530 | 25.647 | USD -4,180 | - |
| 2025-12-15 | BUY | 326 | 26.755 | 25.950 | 26.031 | USD 8,486 | - |
| 2025-12-11 | BUY | 2,189 | 28.590 | 26.499 | 26.708 | USD 58,465 | - |
| 2025-12-04 | BUY | 3,160 | 29.740 | 28.520 | 28.642 | USD 90,509 | - |
| 2025-12-02 | BUY | 2,370 | 29.140 | 28.260 | 28.348 | USD 67,185 | - |
| 2025-11-28 | BUY | 158 | 29.500 | 28.980 | 29.032 | USD 4,587 | - |
| 2025-11-26 | BUY | 474 | 29.990 | 28.530 | 28.676 | USD 13,592 | - |
| 2025-11-26 | BUY | 474 | 29.990 | 28.530 | 28.676 | USD 13,592 | - |
| 2025-11-25 | BUY | 790 | 29.895 | 28.860 | 28.964 | USD 22,881 | - |
| 2025-11-24 | BUY | 158 | 29.450 | 28.000 | 28.145 | USD 4,447 | - |
| 2025-11-20 | SELL | -632 | 29.330 | 27.480 | 27.665 | USD -17,484 | - |
| 2025-11-19 | BUY | 158 | 28.830 | 27.513 | 27.645 | USD 4,368 | - |
| 2025-11-18 | BUY | 948 | 29.000 | 27.150 | 27.335 | USD 25,914 | - |
| 2025-11-17 | BUY | 316 | 29.260 | 27.210 | 27.415 | USD 8,663 | - |
| 2025-11-14 | BUY | 158 | 27.720 | 25.881 | 26.064 | USD 4,118 | - |
| 2025-11-12 | BUY | 158 | 27.180 | 22.000 | 22.518 | USD 3,558 | - |
| 2025-11-10 | BUY | 158 | 23.080 | 21.795 | 21.924 | USD 3,464 | - |
| 2025-11-06 | BUY | 158 | 24.150 | 22.100 | 22.305 | USD 3,524 | - |
| 2025-11-04 | BUY | 158 | 24.165 | 23.000 | 23.117 | USD 3,652 | - |
| 2025-10-30 | BUY | 790 | 24.730 | 23.450 | 23.578 | USD 18,627 | - |
| 2025-10-29 | BUY | 316 | 23.980 | 25.250 | 25.123 | USD 7,939 | - |
| 2025-10-22 | SELL | -632 | 23.280 | 23.490 | 23.469 | USD -14,832 | - |
| 2025-10-20 | BUY | 316 | 22.790 | 23.240 | 23.195 | USD 7,330 | - |
| 2025-10-17 | BUY | 789 | 23.020 | 23.340 | 23.308 | USD 18,390 | - |
| 2025-10-15 | BUY | 1,256 | 22.570 | 22.740 | 22.723 | USD 28,540 | - |
| 2025-10-03 | BUY | 1,106 | 23.230 | 23.600 | 23.563 | USD 26,061 | - |
| 2025-10-02 | BUY | 158 | 23.050 | 23.160 | 23.149 | USD 3,658 | - |
| 2025-09-30 | BUY | 316 | 24.250 | 24.570 | 24.538 | USD 7,754 | - |
| 2025-09-26 | BUY | 316 | 23.260 | 23.480 | 23.458 | USD 7,413 | - |
| 2025-09-25 | BUY | 316 | 23.010 | 23.890 | 23.802 | USD 7,521 | - |
| 2025-09-24 | SELL | -1,986 | 23.970 | 24.130 | 24.114 | USD -47,890 | - |
| 2025-09-18 | BUY | 164 | 22.970 | 23.090 | 23.078 | USD 3,785 | - |
| 2025-09-17 | BUY | 495 | 21.850 | 22.400 | 22.345 | USD 11,061 | - |
| 2025-08-20 | SELL | -656 | 17.280 | 17.530 | 17.505 | USD -11,483 | - |
| 2025-07-30 | BUY | 656 | 16.560 | 17.690 | 17.577 | USD 11,531 | - |
| 2025-07-17 | SELL | -328 | 15.960 | 16.000 | 15.996 | USD -5,247 | - |
| 2025-07-11 | SELL | -1,312 | 14.430 | 14.730 | 14.700 | USD -19,286 | - |
| 2025-07-07 | BUY | 492 | 13.620 | 14.135 | 14.084 | USD 6,929 | - |
| 2025-07-02 | BUY | 9,075 | 13.740 | 13.880 | 13.866 | USD 125,834 | - |
| 2025-06-20 | BUY | 2,570 | 12.430 | 13.020 | 12.961 | USD 33,310 | - |
| 2025-06-11 | BUY | 314 | 12.490 | 12.870 | 12.832 | USD 4,029 | - |
| 2025-06-10 | BUY | 314 | 12.120 | 12.415 | 12.385 | USD 3,889 | - |
| 2025-06-04 | SELL | -156 | 12.530 | 13.440 | 13.349 | USD -2,082 | - |
| 2025-04-23 | BUY | 156 | 13.030 | 13.500 | 13.453 | USD 2,099 | - |
| 2025-04-10 | SELL | -1,248 | 11.270 | 11.780 | 11.729 | USD -14,638 | - |
| 2025-04-08 | SELL | -156 | 10.710 | 12.390 | 12.222 | USD -1,907 | - |
| 2025-04-07 | SELL | -156 | 11.280 | 11.860 | 11.802 | USD -1,841 | - |
| 2025-04-04 | SELL | -780 | 11.680 | 12.760 | 12.652 | USD -9,869 | - |
| 2025-04-01 | BUY | 2,213 | 13.230 | 14.340 | 14.229 | USD 31,489 | - |
| 2025-03-31 | SELL | -453 | 14.380 | 14.890 | 14.839 | USD -6,722 | - |
| 2025-03-21 | BUY | 2,969 | 15.750 | 16.635 | 16.547 | USD 49,127 | - |
| 2025-03-14 | SELL | -2,272 | 17.140 | 17.500 | 17.464 | USD -39,678 | - |
| 2025-03-07 | SELL | -282 | 16.230 | 17.290 | 17.184 | USD -4,846 | - |
| 2025-03-04 | SELL | -142 | 16.330 | 16.440 | 16.429 | USD -2,333 | - |
| 2025-02-25 | BUY | 284 | 15.750 | 16.000 | 15.975 | USD 4,537 | - |
| 2025-02-19 | SELL | -141 | 15.910 | 16.880 | 16.783 | USD -2,366 | - |
| 2025-02-13 | BUY | 420 | 17.620 | 18.330 | 18.259 | USD 7,669 | - |
| 2025-02-12 | BUY | 141 | 18.000 | 18.140 | 18.126 | USD 2,556 | - |
| 2025-02-11 | BUY | 564 | 17.260 | 17.890 | 17.827 | USD 10,054 | - |
| 2024-12-30 | BUY | 4,986 | 16.350 | 16.725 | 16.688 | USD 83,204 | - |
| 2024-11-18 | SELL | -1,830 | 16.100 | 16.157 | 16.151 | USD -29,557 | - |
| 2024-11-08 | SELL | -122 | 16.500 | 16.870 | 16.833 | USD -2,054 | - |
| 2024-10-21 | SELL | -123 | 15.790 | 16.245 | 16.200 | USD -1,993 | - |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of CNTA
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 96,177 | 0 | 334,781 | 28.7% |
| 2025-09-18 | 426,530 | 0 | 753,193 | 56.6% |
| 2025-09-17 | 188,609 | 0 | 1,023,961 | 18.4% |
| 2025-09-16 | 99,365 | 0 | 660,284 | 15.0% |
| 2025-09-15 | 183,432 | 0 | 383,038 | 47.9% |
| 2025-09-12 | 197,758 | 217 | 618,633 | 32.0% |
| 2025-09-11 | 185,370 | 0 | 655,218 | 28.3% |
| 2025-09-10 | 698,631 | 1,100 | 1,910,008 | 36.6% |
| 2025-09-09 | 572,093 | 1,862 | 1,760,168 | 32.5% |
| 2025-09-08 | 642,718 | 0 | 2,271,085 | 28.3% |
| 2025-09-05 | 83,807 | 13 | 214,453 | 39.1% |
| 2025-09-04 | 117,406 | 7,437 | 513,074 | 22.9% |
| 2025-09-03 | 437,623 | 36,858 | 1,631,666 | 26.8% |
| 2025-09-02 | 168,559 | 0 | 321,071 | 52.5% |
| 2025-08-29 | 99,805 | 0 | 265,703 | 37.6% |
| 2025-08-28 | 49,039 | 0 | 136,229 | 36.0% |
| 2025-08-27 | 123,634 | 0 | 442,714 | 27.9% |
| 2025-08-26 | 278,053 | 0 | 572,482 | 48.6% |
| 2025-08-25 | 53,043 | 0 | 132,379 | 40.1% |
| 2025-08-22 | 130,851 | 0 | 443,776 | 29.5% |
| 2025-08-21 | 205,087 | 0 | 526,850 | 38.9% |
| 2025-08-20 | 125,933 | 8,100 | 284,056 | 44.3% |
| 2025-08-19 | 186,848 | 0 | 411,717 | 45.4% |
| 2025-08-18 | 122,693 | 0 | 228,818 | 53.6% |
| 2025-08-15 | 201,318 | 0 | 604,266 | 33.3% |
| 2025-08-14 | 184,418 | 23,957 | 484,620 | 38.1% |
| 2025-08-13 | 168,550 | 0 | 660,965 | 25.5% |
| 2025-08-12 | 140,399 | 0 | 559,815 | 25.1% |
| 2025-08-11 | 137,458 | 0 | 298,824 | 46.0% |
| 2025-08-08 | 118,261 | 0 | 245,078 | 48.3% |
| 2025-08-07 | 164,316 | 0 | 378,798 | 43.4% |
| 2025-08-06 | 164,001 | 0 | 547,575 | 30.0% |
| 2025-08-05 | 190,355 | 0 | 947,019 | 20.1% |
| 2025-08-04 | 209,944 | 0 | 979,067 | 21.4% |
| 2025-08-01 | 166,317 | 0 | 263,607 | 63.1% |
| 2025-07-31 | 389,319 | 100 | 626,955 | 62.1% |
| 2025-07-30 | 758,487 | 0 | 1,534,548 | 49.4% |
| 2025-07-29 | 74,807 | 0 | 126,465 | 59.2% |
| 2025-07-28 | 61,862 | 0 | 218,708 | 28.3% |
| 2025-07-25 | 72,859 | 2,404 | 135,070 | 53.9% |
| 2025-07-24 | 68,706 | 18 | 183,511 | 37.4% |
| 2025-07-23 | 186,112 | 0 | 713,454 | 26.1% |
| 2025-07-22 | 91,728 | 0 | 296,005 | 31.0% |
| 2025-07-21 | 175,405 | 22,136 | 469,215 | 37.4% |
| 2025-07-18 | 134,569 | 0 | 390,014 | 34.5% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Note: All information is provided as is without warranty and should be used for indicative purposes only.
You should independently check data before making any investment decision.
This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.
Copyright Market Footprint Ltd. Privacy Policy